Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
acetylcholine
alpha methyldopa hydrazine
amantadine
amitriptyline
amphetamines
anticholinergic drugs
anticholinergic drugs, side effects of
dementia
depression
dopamine
drug induced neurologic disorders
haloperidol
hypertension
imipramine
L-dopa
L-dopa, drug interactions with and side effects of
L-dopa, potentiators of
monoamine oxidase inhibitors
Parkinson disease
Parkinson disease, drug induced
Parkinson disease, treatment of
Parkinsonism syndrome
parsidol
phenothiazine
procyclidine
ritalin
tricyclic antidepressant
Showing articles 50 to 100 of 336 << Previous Next >>

Levodopa for the Treatment of Parkinsons Disease
NEJM 359:2468-2476, LeWitt,P.A., 2008

Ropinirole 24-Hour Prolonged Release: Randomized, Controlled Study in Advanced Parkinson Disease
Neurol 68:1108-1115, Pahwa,R.,et al, 2007

Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007

Compulsive Singing: Another Aspect of Punding in Parkinsons Disease
Ann Neurol 62:525-528, Bonvin,C.,et al, 2007

Paraneoplastic Anti-N-methyl-D-aspartate Receptor Encephalitis Associated With Ovarian Teratoma
Ann Neurol 61:25-36,3, Dalmau,J.,et al, 2007

Familial Dopa-Responsive Cervical Dystonia
Neurol 66:599-601, Schneider,S.A.,et al, 2006

Benign Tremulous Parkinsonism
Arch Neurol 63:354-357,321, Josephs,K.A.,et al, 2006

Practice Parameter: Diagnosis and Prognosis of New Onset Parkinson Disease (An Evidence-Based Review)
Neurol 66:968-975, Suchowersky,O.,et al, 2006

Practice Parameter: Neuroprotective Strategies and Alternative Therapies for Parkinson Disease (An Evidence-Based Review)
Neurol 66:976-982, Suchowersky,O.,et al, 2006

Dopa-responsive Dystonic Camptocormia
Neurol 66:1779, Van Gerpen,J.A., 2006

Clinicopath Conf, Dopamine-Responsive-Dystonia Caused by a Mutation in the GCH1 Gene
NEJM 355:831-839, Case 26-2006, 2006

Dystonia
NEJM 355:818-829, Tarsy,D. &Simon,D.K., 2006

Developmental Neurotoxivity of Industrial Chemicals
Lancet 368:2167-2178, Grandjean,P. &Landrigan,P.J., 2006

Vascular Parkinsonism and Dementia in a CADASIL Case with Intact Nigrostriatal Dopaminergic System
Akt Neurol 33: Suppl, Wegner,F.,et al, 2006

Dopamine-Responsive Dystonia
eMedicine (Apr), Nikhar,N.K., 2006

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations
Arch Neurol 62:241-248, The PRESTO Study, 2005

"Levodopa Phobia": A New Iatrogenic Cause of Disability in Parkinson Disease
Neurol 64:923-924, Kurlan, R., 2005

Rasagiline as an Adjunct to Levodopa in Patients With Parkinsons Disease and Motor Fluctuations (LARGO, Lasting Effect in Adjunct Therapy With Rasagiline Given Once Daily, Study)
Lancet 365:947-954, 914, Rascol,O., et al, 2005

Methyl Bromide Intoxication Causes Reversible Symmetric Branstem and Cerebellar MRI Lesions
Neurol 64:1279-1281, Geyer,H.L.,et al, 2005

Short-Term Paroxetine Treatment Does Not Alter the Motor Response to Levodopa in PD
Neurol 64:1797-1798, Chung,K.A.,et al, 2005

The Role of Levodopa in the Management of Dementia With Lewy Bodies
JNNP 76:1200-1203, Moloy,S.,et al, 2005

Diagnosis and Initial Management of Parkinsons Disease
NEJM 353:1021-1027, Nutt,J.G.&Wooten,G.F., 2005

Levodopa Addiction in Idiopathic Parkinson Disease
Neurol 65:1508, Borek,L.L &Friedman,J.H., 2005

Diagnosis and Management of Dementia with Lewy Bodies
Neurol 65:1863-1872, McKeith,I.G.,et al, 2005

Effect of Levodopa Treatment for Parkinsonism in Welders
Neurol 62:730-733, Koller,W.C.,et al, 2004

Stalevo for Parkinson's Disease
The Medical Letter 46:39, , 2004

Clinicopath Conf, Multiple-System Atrophy
NEJM 351:912-921, Case 27-2004, 2004

Levodopa and the Progression of Parkinson's Disease
NEJM 351:2498-2508, The Parkinson Study Group, 2004

Restless Legs Syndrome
NEJM 348:2103-2109, Earley,C.J., 2003

Awakenings From Persistent Vegetative State: Report of Three Cases With Parkinsonism and Brain Stem Lesions on MRI
JNNP 74:1571-1573, Matsuda,W.,et al, 2003

Treatments of Parkinson Disease
Arch Neurol 60:1680-1684, Shults,C.W., 2003

Levodopa Addiction in Non-Parkinsonian Patients
Neurol 61:1451, Steiner,I. &Wirguin,I., 2003

Subthalamic DBS Replaces Levodopa in Parkinson's Disease
Neurol 58:396-401, Vingerhoets,F.J.G.,et al, 2002

Practice Parameter: Initiation of Treatment for Parkinson's Disease: An Evidence-based Review
Neurol 58:11-17, Miyasaki,J.M.,et al, 2002

Impact of Sustained Deprenyl (Selegiline) in Levodopa-Treated Parkinson's Disease: A Randomized Placebo-Controlled Extension of the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism Trial
Ann Nuerol 51:604-612, Shoulson,I.,et al, 2002

Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression
JAMA 287:1653-1661, Parkinson Study Group, 2002

Cranial MR Findings in Chronic Toluene Abuse by Inhalation
AJNR 23:1173-1179,1072, Aydin, K.,et al, 2002

Safety and Efficacy of Pallidal or Subthalamic Nucleus Stimulation in Advanced PD
Neurol 56:548-551, Volkmann,J.,et al, 2001

Subclinical Dopaminergic Dysfunction in Asymptomatic Parkinson's Disease Patients' Relatives with a Decreased Sense of Smell
Ann Neurol 50:34-41, Berendse,H.W.,et al, 2001

Effects of Bilateral Subthalamic Nucleus Stimulation on Parkinsonian Gait
Neurol 57:144-146, Stolze,H.,et al, 2001

Ten-year Follow-up of Three Different Initial Treatments in De-novo PD
Neurol 57:1687-1694, Lees,A.J.,et al, 2001

Spinocerebellar Ataxia Type 2 Presenting as Familial Levodopa-Responsive Parkinsonism
Ann Neurol 50:812-815, Shan,D.,et al, 2001

Occupational Exposure to Methyl Isobutyl Ketone Causes Lasting Impairment in Working Memory
Neurol 54:1853-1855, Grober,E.&Schaumburg,H.H., 2000

Axial Parkinsonian Symptoms Can Be Improved: The Role of Levodopa and Bilateral Subthalamic Stimulation
JNNP 68:595-600, Bejjani,B.P.,et al, 2000

Quetiapine for L-Dopa-Induced Psychosis in PD
Neurol 54:1538, Weiner,W.J.,et al, 2000

A Five-Year Study of the Incidence of Dyskinesia in Patients With Early Parkinson's Disease who were Treated with Ropinirole or Levodopa
NEJM 342:1484-1491, Rascol,O.,et al, 2000

The Catechol-O-Methyltransferase (COMT) Inhibitor Entacapone Enhances the Pharmacokinetic and Clinical Response to Sinemet CR in Parkinson's Disease
JNNP 68:589-594, Piccinni,P.,et al, 2000

Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease
JAMA 284:1931-1938,1971, Parkinson Study Group, 2000

A Controlled Study of Additional sr-L-dopa in L-dopa-responsive Restless Legs Syndrome with Late-Night Symptoms
Neurol 52:285-290, Collado-Seidel,V.,et al, 1999

Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
NEJM 340:757-763,801, The Parkinson Study Group, 1999



Showing articles 50 to 100 of 336 << Previous Next >>